234.19
Davita Inc stock is traded at $234.19, with a volume of 138.55K.
It is down -0.92% in the last 24 hours and up +12.13% over the past month.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
See More
Previous Close:
$237.28
Open:
$237.11
24h Volume:
138.55K
Relative Volume:
0.17
Market Cap:
$15.04B
Revenue:
$13.84B
Net Income/Loss:
$1.10B
P/E Ratio:
22.48
EPS:
10.4185
Net Cash Flow:
$1.49B
1W Performance:
+1.51%
1M Performance:
+12.13%
6M Performance:
+115.36%
1Y Performance:
+60.98%
Davita Inc Stock (DVA) Company Profile
Name
Davita Inc
Sector
Industry
Phone
310-536-2668
Address
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, FMS, EHC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DVA
Davita Inc
|
234.31 | 15.03B | 13.84B | 1.10B | 1.49B | 10.42 |
|
HCA
Hca Healthcare Inc
|
373.33 | 82.17B | 76.39B | 7.81B | 7.93B | 29.08 |
|
THC
Tenet Healthcare Corp
|
196.93 | 16.74B | 21.46B | 2.65B | 3.35B | 19.23 |
|
FMS
Fresenius Medical Care Ag Adr
|
24.41 | 12.93B | 22.44B | 1.35B | 2.03B | 1.9002 |
|
EHC
Encompass Health Corp
|
111.45 | 11.16B | 6.07B | 793.80M | 464.40M | 5.9914 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Aug-07-23 | Upgrade | UBS | Neutral → Buy |
| Nov-01-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-31-22 | Downgrade | UBS | Buy → Neutral |
| Aug-19-22 | Resumed | UBS | Buy |
| Jun-21-22 | Reiterated | BofA Securities | Underperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-12-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-26-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-24-20 | Upgrade | Goldman | Neutral → Buy |
| Nov-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-25-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-11-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-26-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-19 | Upgrade | UBS | Sell → Neutral |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Dec-14-18 | Initiated | Barclays | Overweight |
| Nov-28-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-16-18 | Initiated | UBS | Sell |
| Nov-08-18 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Sep-13-18 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-04-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-12-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-11-17 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-17 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-17 | Downgrade | Jefferies | Buy → Hold |
| Dec-13-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Davita Inc Stock (DVA) Latest News
DaVita stock holds on dialysis revenue and margin trends - Ad-hoc-news.de
DaVita Inc. to announce Q2FY26 results on August 4 - scanx.trade
DaVita schedules Q2 earnings call for August 4, 2026, after market close. - Pluang
DaVita Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call - Arizona Daily Star
What you need to know ahead of DaVita’s earnings release - MSN
DaVita stock trades steady as dialysis operator highlights cash flow and growth investments - Ad-hoc-news.de
DaVita stock holds firm as earnings and cash flow support dialysis strategy - Ad-hoc-news.de
DaVita stock benefits from expanding community-based kidney care - MSN
DaVita stock trades steadily as dialysis margins and leverage stay in focus - Ad-hoc-news.de
DaVita stock trades steady as chronic kidney care demand supports earnings trajectory - ad-hoc-news.de
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors - Yahoo Finance
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita Wins Bid To Decertify 1,300-Member Collective - Law360
DaVita: Why We Exited Our Position In Q2 (DVA) - Seeking Alpha
DaVita gains 21.4% in three months: How should you play the stock? - MSN
DaVita stock trades steadily as kidney care margins and cash flow support valuation - Ad-hoc-news.de
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
DaVita Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DaVita shares more than double after strong Q1 and court win; analyst sells most shares, rates Hold. - Pluang
DaVita: I Believe This Is Overvalued (NYSE:DVA) - Seeking Alpha
What You Need To Know Ahead of DaVita’s Earnings Release - Yahoo Finance
DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Truist Raises Price Target on DaVita to $250 From $205, Keeps Hold Rating - Moomoo
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $250 - Moomoo
DaVita expands comprehensive kidney care through dialysis services - MSN
DaVita Company Profile & Introduction - Moomoo
DaVita stock holds steady as kidney care specialist focuses on operations and long-term dialysis dem - ad-hoc-news.de
DaVita Inc. (DVA) Stock Analysis: Strong ROE And Growth Potential In Healthcare Sector - DirectorsTalk Interviews
Exciting News for Farmington: DaVita Maple Valley is Expandi... - Park Hills Daily Journal
DaVita stock reflects steady dialysis demand amid US healthcare focus - ad-hoc-news.de
DVA stock holds steady as dialysis demand underpins the long-term case - ad-hoc-news.de
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why - Yahoo Finance
DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says - Moomoo
DaVita stock holds steady as kidney care demand supports long term outlook - ad-hoc-news.de
UBS Adjusts Price Target on DaVita to $270 From $235 - marketscreener.com
Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026. - The Motley Fool
DAVITA INC. : BARCLAYS RAISES TARGET PRICE TO $218 FROM $194 - Moomoo
DaVita Inc focus on kidney care operations as investors watch US healthcare demand - Ad-hoc-news.de
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
DaVita stock benefits from strengthening kidney care delivery - MSN
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DaVita Inc. focuses on core dialysis services as investors watch U.S. healthcare trends - ad-hoc-news.de
Barclays Adjusts Price Target on DaVita to $218 From $194 - Moomoo
DaVita (DVA) Q2 2024 earnings summary - Quartr
The DaVita In-Center HemodialysisA core service tailored to U.S. kidney patients - ad-hoc-news.de
DaVita Stock On Fire: Up 13% With 10-Day Winning Streak - Trefis
DaVita Inc. on Track for Record High Close -- Data Talk - Moomoo
DaVita Stock Rockets 13% With 10-Day Winning Streak - Trefis
DaVita Inc. outlines growth path as kidney care demand rises - AD HOC NEWS
DaVita Inc and its role in the US dialysis market. Long-term fundamentals and business model in focu - AD HOC NEWS
Davita Inc Stock (DVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):